StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
DepoMed Inc (DEPO) PT Lowered to $6 at RBC Capital Following 3Q Miss
November 8, 2017 8:13 AM
RBC Capital lowered its price target on DepoMed Inc (NASDAQ: DEPO) to $6.00 (from $8.00) while maintaining a Sector ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst PT Change
Next Articles
Depomed (DEPO) Tops Q3 EPS by 3c, Revenue Comes in Light
November 7, 2017 4:22 PM
Depomed Announces Third Quarter 2017 Financial Results
November 7, 2017 4:07 PM
Depomed (DEPO) to Acquire U.S. Rights to Cosyntropin, Divest Lazanda in Pact with Slan
November 7, 2017 4:03 PM
Depomed and Slán Medicinal Holdings Ltd Announce Strategic Asset Transactions
November 7, 2017 4:00 PM